These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 5715725)

  • 41. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
    Millet J; Jouault SC; Mauray S; Theveniaux J; Sternberg C; Boisson Vidal C; Fischer AM
    Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Action of cobalt compounds on vascular permeability, mast cells and blood clotting in rats and rabbits.
    Fiedler H
    J Pharm Pharmacol; 1970 Aug; 22(8):648. PubMed ID: 4394555
    [No Abstract]   [Full Text] [Related]  

  • 43. Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
    Yamashita J; Nakajima K; Ohno Y; Kaneshiro Y; Matsuo T; Tanaka H; Kaneko K
    Eur J Pharmacol; 2008 Jul; 589(1-3):239-44. PubMed ID: 18541230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thiozyloside compound.
    Masson P; Theveniaux J; Coup D; Grégoire T; Vaillot M; Dupouy D; Sié P; Boneu B; Millet J
    Thromb Haemost; 1999 Jun; 81(6):945-50. PubMed ID: 10404773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The effect of new synthetic prostanoids on the indices of the blood coagulation system].
    Petrukhina GN; Makarov VA; Freĭmanis IaF; Lozha EV; Sirotenko AV
    Eksp Klin Farmakol; 1995; 58(5):37-40. PubMed ID: 8704588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cobalt effects in the organism with special reference to cardiovascular effects].
    Achenbach H; Urbaszek W
    Z Gesamte Inn Med; 1972 Oct; 27(19):809-16. PubMed ID: 4567175
    [No Abstract]   [Full Text] [Related]  

  • 47. [Intraperitoneal administration of fibrinolysin and blood coagulation].
    Zhenchevskiĭ RA
    Sov Med; 1969 Dec; 32(12):32-6. PubMed ID: 4246577
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of the nerve growth factor on blood coagulation and fibrinolysis].
    Isanbaev ChI; Vypova NL; Kazantseva DS; Sagdiev N
    Eksp Klin Farmakol; 1997; 60(3):45-7. PubMed ID: 9324398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Changes in coagulability following a fat-emulsion therapy].
    Amris CJ; Brockner J; Larsen V
    Wien Med Wochenschr; 1967 Jan; 117(2):27-31. PubMed ID: 5590804
    [No Abstract]   [Full Text] [Related]  

  • 50. [Antithrombin activity of the aortic wall in rats kept on an atherogenic diet].
    Oborina IuN; Nikitin IuP
    Vopr Pitan; 1969; 28(6):29-31. PubMed ID: 5380241
    [No Abstract]   [Full Text] [Related]  

  • 51. Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors.
    Gronewold TM; Glass S; Quandt E; Famulok M
    Biosens Bioelectron; 2005 Apr; 20(10):2044-52. PubMed ID: 15741074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Standardization of the laboratory method for antithrombin activity measurement].
    Okajima K
    Rinsho Byori; 2002 Mar; 50(3):283-6. PubMed ID: 11985057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
    Dempfle CE; Eichner J; Suvajac N; Ahmad-Nejad P; Neumaier M; Borggrefe M
    Anesth Analg; 2009 Sep; 109(3):712-6. PubMed ID: 19690236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6.
    Undar L; Ertuğrul C; Altunbaş H; Akça S
    Thromb Haemost; 1999 Apr; 81(4):571-5. PubMed ID: 10235441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fat infusions and blood coagulation. Effect of various fat emulsions on blood coagulability. A comparative study.
    Brockner J; Amris CJ; Larsen V
    Acta Chir Scand Suppl; 1965; 343():48-55. PubMed ID: 5214023
    [No Abstract]   [Full Text] [Related]  

  • 56. [Lengthening of the thrombin time due to an anti-equine antithrombin in a case of hyperthrombocytic myelosis].
    Favre-Gilly J; Thouverez JP; Belleville J; Croizat P
    Lyon Med; 1966 May; 215(20):1351-5. PubMed ID: 5932766
    [No Abstract]   [Full Text] [Related]  

  • 57. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
    Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
    Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
    Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
    Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade.
    Dong H; Chen SX; Kini RM; Xu HX
    J Nat Prod; 1998 Nov; 61(11):1356-60. PubMed ID: 9834152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Blood coagulation activities of the vascular intima. 10. Intimal antithrombin of the human aorta].
    Ota G; Tsubokawa Y; Masaoka N
    Igaku To Seibutsugaku; 1968 Sep; 77(3):101-5. PubMed ID: 5750581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.